These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2055727)

  • 1. Extravascular toxicity of two magnetic resonance contrast agents. Preliminary experience in the rat.
    Cohan RH; Leder RA; Herzberg AJ; Hedlund LW; Wheeler CT; Beam CA; Nadel SN; Dunnick NR
    Invest Radiol; 1991 Mar; 26(3):224-6. PubMed ID: 2055727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerance of extracellular contrast agents for magnetic resonance imaging.
    Weinmann HJ; Press WR; Gries H
    Invest Radiol; 1990 Sep; 25 Suppl 1():S49-50. PubMed ID: 2283256
    [No Abstract]   [Full Text] [Related]  

  • 3. Local tissue toxicity in response to extravascular extravasation of magnetic resonance contrast media.
    Runge VM; Dickey KM; Williams NM; Peng X
    Invest Radiol; 2002 Jul; 37(7):393-8. PubMed ID: 12068161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotoxicity of contrast media for magnetic resonance imaging after generalized breakdown of the blood-brain barrier.
    Evill CA; Wilson AJ; Fletcher MC; Sage MR
    Acad Radiol; 1996 Aug; 3 Suppl 2():S336-8. PubMed ID: 8796597
    [No Abstract]   [Full Text] [Related]  

  • 5. Extravascular extravasation of radiographic contrast media. Effects of conventional and low-osmolar agents in the rat thigh.
    Cohan RH; Leder RA; Bolick D; Herzberg AJ; Hedlund LW; Wheeler CT; Helms MJ; Dunnick NR
    Invest Radiol; 1990 May; 25(5):504-10. PubMed ID: 2345080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo quantification of the blood-brain barrier injury using magnetic resonance enhancement.
    Hayakawa K; Yamashita K; Mitsumori M; Nakano Y
    Invest Radiol; 1990 Sep; 25 Suppl 1():S80-1. PubMed ID: 2283266
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in macrocyclic gadolinium complexes as magnetic resonance imaging contrast agents.
    Meyer D; Schaefer M; Doucet D
    Invest Radiol; 1990 Sep; 25 Suppl 1():S53-5. PubMed ID: 2132570
    [No Abstract]   [Full Text] [Related]  

  • 8. New magnetic resonance imaging contrast agents for infarct imaging based on phosphonate derivatives of Gd-DTPA.
    Adzamli IK; Blau M; Pfeffer MA; Davis MA
    Invest Radiol; 1991 Nov; 26 Suppl 1():S242-4; discussion S245-7. PubMed ID: 1808139
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic cisplatin nephropathy, contrast media, and creatinine.
    Thomsen HS; Dorph S; Larsen S; Horn T; Hemmingsen L; Skaarup P; Golman K; Svendsen O
    Acad Radiol; 1996 Aug; 3 Suppl 2():S444-6. PubMed ID: 8796625
    [No Abstract]   [Full Text] [Related]  

  • 10. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
    Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
    Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of Gd-dimeglumine on subcutaneous tissues: a study with rats.
    McAlister WH; McAlister VI; Kissane JM
    AJNR Am J Neuroradiol; 1990; 11(2):325-7. PubMed ID: 2107714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An experimental study on the neurotolerability of gadobenate dimeglumine in a rat model of focal brain ischemia.
    La Noce A; Miragoli L; Samuelli G; Tirone P
    Invest Radiol; 1996 Sep; 31(9):550-5. PubMed ID: 8877491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paramagnetic liposomes as magnetic resonance contrast agents.
    Unger E; Tilcock C; Ahkong QF; Fritz T
    Invest Radiol; 1990 Sep; 25 Suppl 1():S65-6. PubMed ID: 2283260
    [No Abstract]   [Full Text] [Related]  

  • 14. The functional effects of gadolinium-DTPA on the isolated perfused rat kidney.
    Brown PW; Haylor JL; Morcos SK; el Nahas AM
    Eur J Radiol; 1993 Feb; 16(2):85-9. PubMed ID: 8462585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative study between Gd-BOPTA, a biliary excretion contrast medium, and Gd-DTPA in the magnetic resonance imaging of the rat liver].
    Patrizio G; Pavone P; Cardone G; Pietroletti R; Passariello R; Tettamanti E; Musu C; Felder E
    Radiol Med; 1990 May; 79(5):458-62. PubMed ID: 2359853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging.
    Lauffer RB; Parmelee DJ; Ouellet HS; Dolan RP; Sajiki H; Scott DM; Bernard PJ; Buchanan EM; Ong KY; Tyeklár Z; Midelfort KS; McMurry TJ; Walovitch RC
    Acad Radiol; 1996 Aug; 3 Suppl 2():S356-8. PubMed ID: 8796603
    [No Abstract]   [Full Text] [Related]  

  • 17. An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis.
    Bartolini ME; Pekar J; Chettle DR; McNeill F; Scott A; Sykes J; Prato FS; Moran GR
    Magn Reson Imaging; 2003 Jun; 21(5):541-4. PubMed ID: 12878264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The synthesis and screening of nonionic gadolinium (III) DTPA-bisamide complexes as magnetic resonance imaging contrast agents.
    Periasamy M; White D; deLearie L; Moore D; Wallace R; Lin W; Dunn J; Hirth W; Cacheris W; Pilcher G
    Invest Radiol; 1991 Nov; 26 Suppl 1():S217-20; discussion S232-5. PubMed ID: 1667003
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety aspects and pharmacokinetics of inhaled aerosolized gadolinium.
    Berthezène Y; Mühler A; Lang P; Shames DM; Clément O; Rosenau W; Kuwatsuru R; Brasch RC
    J Magn Reson Imaging; 1993; 3(1):125-30. PubMed ID: 8428078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of contrast media for magnetic resonance imaging.
    Goldstein HA; Wiggins JR; Kashanian F
    Ann N Y Acad Sci; 1992 Mar; 649():322-31. PubMed ID: 1580503
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.